Gaboxadol or 4,5,6,7-
tetrahydroisoxazolo-[5,4-c]pyridine-
3-ol (THIP) is a selective agonist for the
3b4;-subunit containing extrasynaptic GABA
A receptors that will soon enter the U.S. market as a sleep aid [Winsky-Sommerer R, Vyazovskiy VV, Homanics GE, Tobler I (2007) The EEG effects of THIP (gaboxadol) on sleep and waking are mediated by the GABA(A)delta-subunit-containing receptors. Eur J Neurosci 25:189
3ȁ
3;1899]. Numerous studies have shown that systemic administration of THIP reduces wakefulness and increases sleep both in humans and rats [
Lancel M, Langebartels A (2000) Gamma-aminobutyric acid(A) (GABA(A)) agonist 4,5,6,7-
tetrahydroisoxazolo[4,5-c]pyridin-
3-ol persistently increases sleep maintenance and intensity during chronic administration to rats. J Pharmacol Exp Ther 29
3:1084ȁ
3;1090;
37">37">Walsh JK, Deacon S, Dijk DJ, Lundahl J (2007) The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia. Sleep
30:59
3ȁ
3;602]. However, it is yet unclear where in the brain THIP acts to promote sleep. Since the perifornical lateral hypothalamus (PFH) contains orexin neurons and orexin neurons are critical for maintenance of arousal [McCarley RW (2007) Neurobiology of rapid eye movement (REM) and NREM sleep. Sleep Med 8:
302ȁ
3;
330], we hypothesized that THIP may act on PFH neurons to promote sleep. To test our hypothesis, we used reverse microdialysis to perfuse THIP unilaterally into the PFH and studied its effects on sleepȁ
3;wakefulness during the light period in freely behaving rats.